GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kronos Bio Inc (NAS:KRON) » Definitions » 5-Year Yield-on-Cost %

KRON (Kronos Bio) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 23, 2025)


View and export this data going back to 2020. Start your Free Trial

What is Kronos Bio 5-Year Yield-on-Cost %?

Kronos Bio's yield on cost for the quarter that ended in Dec. 2024 was 0.00.


The historical rank and industry rank for Kronos Bio's 5-Year Yield-on-Cost % or its related term are showing as below:



KRON's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.66
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Kronos Bio's 5-Year Yield-on-Cost %

For the Biotechnology subindustry, Kronos Bio's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kronos Bio's 5-Year Yield-on-Cost % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kronos Bio's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Kronos Bio's 5-Year Yield-on-Cost % falls into.


;
;

Kronos Bio 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Kronos Bio is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Kronos Bio  (NAS:KRON) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Kronos Bio 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Kronos Bio's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kronos Bio Business Description

Traded in Other Exchanges
N/A
Address
1300 So. El Camino Real, Suite 400, San Mateo, CA, USA, 94402
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
Executives
Norbert W Bischofberger director, 10 percent owner, officer: President & CEO 333 LAKESIDE DR, C/O GILEAD SCIENCES, INC., FOSTER CITY CA 94404
Jorge Dimartino officer: Chief Medical Officer & VP C/O KRONOS BIO, INC., 1300 S, SAN MATEO CA 94402
Christopher Dinsmore officer: Chief Scientific Officer C/O KRONOS BIO, INC., 1300 EL CAMINO REAL, STE. 300, SAN MATEO CA 94402
Barbara Kosacz officer: COO & General Counsel 3175 HANOVER STREET, PALO ALTO CA 94304
Sandra A. Gardiner officer: Interim CFO CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Yasir B. Al-wakeel officer: Chief Financial Officer MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Katherine V Stultz director C/O GRAPHITE BIO, INC., 279 EAST GRAND AVENUE, SUITE 430, SOUTH SAN FRANCISCO CA 94080
Backer Marianne De director 177 E COLORADO BLVD, SUITE 700, PASADENA CA 91105
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Jakob Loven director C/O ARVINAS, INC., 5 SCIENCE PARK, 395 WINCHESTER AVENUE, NEW HAVEN CT 06511
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Otello Stampacchia director, 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Elena Ridloff director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130